Swedish Orphan Biovitrum Dividend

Dividend criteria checks 0/6

Swedish Orphan Biovitrum does not have a record of paying a dividend.

Key information

n/a

Dividend yield

n/a

Payout ratio

Industry average yield	1.8%
Next dividend pay date	n/a
Ex dividend date	n/a
Dividend per share	n/a
Earnings per share	kr6.30
Dividend yield forecast in 3Y	0%

Recent dividend updates

No updates

Recent updates

Swedish Orphan Biovitrum AB (publ) Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

Apr 27

Investors Still Waiting For A Pull Back In Swedish Orphan Biovitrum AB (publ) (STO:SOBI)

Apr 24

Swedish Orphan Biovitrum AB (publ) Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Apr 06

Swedish Orphan Biovitrum (STO:SOBI) Seems To Use Debt Quite Sensibly

Mar 05

Swedish Orphan Biovitrum's (STO:SOBI) Weak Earnings May Only Reveal A Part Of The Whole Picture

Feb 15

Swedish Orphan Biovitrum AB (publ)'s (STO:SOBI) Earnings Haven't Escaped The Attention Of Investors

Jan 17

These 4 Measures Indicate That Swedish Orphan Biovitrum (STO:SOBI) Is Using Debt Reasonably Well

Dec 27

Is Swedish Orphan Biovitrum (STO:SOBI) A Risky Investment?

Sep 28

Is Swedish Orphan Biovitrum (STO:SOBI) Using Too Much Debt?

Jun 26

Swedish Orphan Biovitrum (STO:SOBI) Has A Somewhat Strained Balance Sheet

Mar 28

Is Swedish Orphan Biovitrum AB (publ) (STO:SOBI) Trading At A 30% Discount?

Nov 17

Is Swedish Orphan Biovitrum (STO:SOBI) A Risky Investment?

Sep 19

An Intrinsic Calculation For Swedish Orphan Biovitrum AB (publ) (STO:SOBI) Suggests It's 50% Undervalued

Aug 12

Here's Why Swedish Orphan Biovitrum (STO:SOBI) Has A Meaningful Debt Burden

Jun 04

Stability and Growth of Payments

Fetching dividends data

Stable Dividend: Insufficient data to determine if SOBI's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if SOBI's dividend payments have been increasing.

Dividend Yield vs Market

Swedish Orphan Biovitrum Dividend Yield vs Market

How does SOBI dividend yield compare to the market?
Segment	Dividend Yield
Company (SOBI)	n/a
Market Bottom 25% (SE)	1.5%
Market Top 25% (SE)	4.3%
Industry Average (Biotechs)	1.8%
Analyst forecast in 3 Years (SOBI)	0%

Notable Dividend: Unable to evaluate SOBI's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate SOBI's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate SOBI's payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as SOBI has not reported any payouts.

Discover strong dividend paying companies

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Swedish Orphan Biovitrum Dividend

Dividend criteria checks 0/6

Key information

Recent dividend updates

Recent updates

Swedish Orphan Biovitrum AB (Publ) Provides Earnings Guidance for 2024

Swedish Orphan Biovitrum AB (publ) Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

Swedish Orphan Biovitrum AB (publ) to Report Q4, 2024 Results on Feb 05, 2025

First quarter 2024 earnings released: EPS: kr2.35 (vs kr3.60 in 1Q 2023)

Investors Still Waiting For A Pull Back In Swedish Orphan Biovitrum AB (publ) (STO:SOBI)

Swedish Orphan Biovitrum AB (publ) Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Full year 2023 earnings: EPS misses analyst expectations

Swedish Orphan Biovitrum (STO:SOBI) Seems To Use Debt Quite Sensibly

Swedish Orphan Biovitrum AB (publ) to Report Fiscal Year 2023 Final Results on Apr 02, 2024

Head of Technical Operations recently sold kr5.7m worth of stock

Swedish Orphan Biovitrum's (STO:SOBI) Weak Earnings May Only Reveal A Part Of The Whole Picture

Full year 2023 earnings: EPS misses analyst expectations

Swedish Orphan Biovitrum AB (Publ) Provides Revenue Guidance for the Year 2024

Swedish Orphan Biovitrum AB (publ)'s (STO:SOBI) Earnings Haven't Escaped The Attention Of Investors

Swedish Orphan Biovitrum AB (Publ) Announces Resignation of Bo Jesper Hansen as Chairman of the Board and Board Member

Is Swedish Orphan Biovitrum (STO:SOBI) A Risky Investment?

Senior Scientific & Medical Advisor recently sold kr16m worth of stock

Swedish Orphan Biovitrum AB (publ), Annual General Meeting, May 14, 2024

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Sobi and Apellis Pharmaceuticals, Inc. Announce Positive Results from Phase 2 NOBLE Results of Pegcetacoplan in Post-Transplant Recurrence of Primary IC-MPGN and C3G

Sobi Appoints Lydia Abad-Franch as Head of R&D and Chief Medical Officer

Sanofi S.A. and Sobi Announce Once-Weekly ALTUVIIIO Approved in Japan as A New Class of Factor VIII Therapy for Hemophilia A

Independent Director recently bought kr439k worth of stock

New minor risk - Shareholder dilution

Swedish Orphan Biovitrum AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 6.023593 billion.

Independent Director recently bought kr439k worth of stock

Swedish Orphan Biovitrum AB (publ) to Report Q3, 2024 Results on Oct 24, 2024

New major risk - Financial position

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus EPS estimates increase by 12%

Is Swedish Orphan Biovitrum (STO:SOBI) Using Too Much Debt?

Swedish Orphan Biovitrum AB (publ) (OM:SOBI) completed the acquisition of CTI BioPharma Corp. (NasdaqCM:CTIC) from a group of shareholders.

Head of International recently sold kr386k worth of stock

European Medicines Agency Validates Sobi's Marketing Authorisation Application for Efanesoctocog Alfa for Treatment of Haemophilia A

Independent Chairman recently bought kr11m worth of stock

Less than half of directors are independent

Swedish Orphan Biovitrum AB (publ) (OM:SOBI) entered into a definitive agreement and plan of merger to acquire CTI BioPharma Corp. (NasdaqCM:CTIC) from a group of shareholders for $1.2 billion.

Swedish Orphan Biovitrum AB (Publ) Approves Election of Christophe Bourdon and Anders Ullman as Members of the Board

Full year 2022 earnings: EPS in line with analyst expectations despite revenue beat

Is Swedish Orphan Biovitrum (STO:SOBI) A Risky Investment?

Head of Europe recently sold kr15m worth of stock

CEO & President recently sold kr24m worth of stock

Full year 2022 earnings: EPS in line with analyst expectations despite revenue beat

Swedish Orphan Biovitrum AB (Publ) Provides Earnings Guidance for 2023

Swedish Orphan Biovitrum AB (Publ) Announces Executive Changes

Is Swedish Orphan Biovitrum AB (publ) (STO:SOBI) Trading At A 30% Discount?

These 4 Measures Indicate That Swedish Orphan Biovitrum (STO:SOBI) Is Using Debt Reasonably Well

ADC Therapeutics SA and Swedish Orphan Biovitrum AB Announce the European Commission Approval of Zynlonta® (Loncastuximab Tesirine)

Sobi North America, the North American Affiliate of Swedish Orphan Biovitrum AB Announces That U.S. Food and Drug Administration Issues Emergency Use Authorization for Kineret® (Anakinra) for the Treatment of Covid-19-Related Pneumonia

Swedish Orphan Biovitrum AB (Publ)'s Chairman of the Board Håkan Björklund Will Not Be Available for Re-Election At the Annual General Meeting 2023

Swedish Orphan Biovitrum AB (publ) to Report Q3, 2023 Results on Oct 26, 2023

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Is Swedish Orphan Biovitrum (STO:SOBI) A Risky Investment?

ADC Therapeutics and Sobi Announce ZYNLONTA® (loncastuximab tesirine) Receives Positive CHMP Opinion in Europe for the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma

Sanofi and Sobi Announce US Food and Drug Administration Accept Priority Review the Biologics License Application for efanesoctocog alfa

Swedish Orphan Biovitrum AB (publ) Provides Revenue Guidance for the Year 2022

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Is Swedish Orphan Biovitrum (STO:SOBI) Using Too Much Debt?

Apellis Pharmaceuticals, Inc. and Sobi(R) Report New Data Reinforcing the Robust Efficacy and Safety Profile of EMPAVELI (pegcetacoplan) for PNH at EHA 2022 Congress

Apellis Pharmaceuticals, Inc. and Sobi Announces First Patient Dosed in Phase 3 VALIANT Study of Pegcetacoplan for IC-MPGN and C3G, Rare Kidney Diseases with High Unmet Medical Need

FDA Grants efanesoctocog alfa Breakthrough Therapy Designation for Hemophilia A by Sanofi and Sobi

Swedish Orphan Biovitrum AB (publ) Elects Bo Jesper Hansen as New Board Member

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus forecasts updated

Swedish Orphan Biovitrum (STO:SOBI) Has A Somewhat Strained Balance Sheet

Sanofi and Swedish Orphan Biovitrum AB Announce Positive Topline Results from the Pivotal XTEND-1 Phase 3 Study

Gamifant (Emapalumab) Recommends for Approval in China for Treatment of Primary Haemophagocytic Lymphohistiocytosis (HLH)

Swedish Orphan Biovitrum AB (publ), Annual General Meeting, May 10, 2022

Kineret® (Anakinra) Receives Positive Opinion from the Committee for Medicinal Products for Human Use of the European Medicines Agency for Treatment of Patients with Covid-19 Pneumonia

Apellis Pharmaceuticals, Inc. and Swedish Orphan Biovitrum AB (Publ) Announce EU Approval of Aspaveli® (Pegcetacoplan) for Treatment of PNH

Apellis Pharmaceuticals, Inc. and Swedish Orphan Biovitrum AB (publ) Report Empaveli™ Demonstrated Sustained Normalization of Clinical Measures in a Broad PNH Patient Population

Advent International Corporation and GIC Special Investments Pte. Ltd. cancelled the acquisition of Swedish Orphan Biovitrum AB (publ) (OM:SOBI) from Investor AB (publ) (OM:INVE A), AP Fonden 4 and others.

Investor sentiment deteriorated over the past week

Head of Technical Operations recently bought kr1.3m worth of stock

Is Swedish Orphan Biovitrum AB (publ) (STO:SOBI) Trading At A 30% Discount?